How did CTKB's Q1 2025 EPS forecast compare to past trends?

Cytek Biosciences (CTKB) is forecasted to have an EPS of -$0.05 in Q1 2025, which is an improvement compared to the -$0.02 EPS reported in Q1 2023. However, when compared to Q1 2024, the -$0.05 EPS represents a decline from the -$0.02 EPS reported in that quarter. This indicates a challenging trend for CTKB's earnings in the near term, with a deterioration in the latest quarter's performance compared to the previous year's same period.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|CTKB|CTKB.O|Cytek Biosciences|2022 Q2||0|185|
|CTKB|CTKB.O|Cytek Biosciences|2022 Q3||0.01|185|
|CTKB|CTKB.O|Cytek Biosciences|2023 Q1|-150|-0.05|185|
|CTKB|CTKB.O|Cytek Biosciences|2023 Q2||-0.03|185|
|CTKB|CTKB.O|Cytek Biosciences|2023 Q3|-600|-0.05|185|
|CTKB|CTKB.O|Cytek Biosciences|2024 Q1|0|-0.05|185|
|CTKB|CTKB.O|Cytek Biosciences|2024 Q2|-166.66666666666669|-0.08|185|
|CTKB|CTKB.O|Cytek Biosciences|2024 Q3|120|0.01|185|